<DOC>
	<DOC>NCT01145560</DOC>
	<brief_summary>The primary purpose of this study to evaluate the effect of two different doses of AZD9773 (CytoFab™) versus placebo on ventilator free days (VFDs) over the first 28 days after the start of dosing with AZD9773 in patients with severe sepsis and/or septic shock, who are already receiving appropriate standard of care treatment for sepsis.</brief_summary>
	<brief_title>A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock</brief_title>
	<detailed_description />
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock, Septic</mesh_term>
	<criteria>Adults with a first episode of sepsis during this hospitalisation and objective evidence of infection that requires parenteral antibiotics. At least 2 of 4 SIRS criteria in the 24 hours before organ dysfunction (must include either fever OR elevated white blood cells [WBC]) Cardiovascular or respiratory dysfunction. Immunocompromising comorbidities or concomitant medications: 1. Advanced human immunodeficiency virus (HIV) infection (CD4 ≤50/mm3). 2. Stage III or IV cancer. 3. Haemopoietic or lymphoreticular malignancies not in remission. 4. Receiving radiation therapy or chemotherapy. 5. Stem cell, organ or bone marrow transplant in the past 6 months. 6. Absolute neutrophil count &lt;500 per μL. 7. High dose steroids or other immunocompromising drugs. Concomitant diseases: 1. Deep seated fungal infection or active tuberculosis. 2. Cirrhosis with portal hypertension or ChildsPugh Class C. 3. History of chronic hypercarbia, respiratory failure in past 6 months or use of home oxygen in the setting of severe chronic respiratory disease. 4. Neuromuscular disorders that impact breathing/spontaneous ventilation. 5. Quadriplegia. 6. Cardiac arrest in the past 30 days. 7. New York Heart Association functional Class IV due to heart failure or any disorder. 8. Burns over &gt; 30% of body surface area. Medication and allergy disqualifications. 1. Treatment with antiTNF agents within the last 8 weeks. 2. Previously received ovine derived products (CroFab™, DigiFab™). 3. Sheep product allergy or allergy to latex, papain, chymopapain.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>severe sepsis</keyword>
	<keyword>TNF neutralisation</keyword>
	<keyword>septic shock patients</keyword>
</DOC>